Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141⁺ dendritic cells to activate naive and memory NY-ESO-1-specific CD8⁺ T cells.

ABSTRACT:

Background

Dendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8⁺ T-cell-mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery of immunogenic tumor antigens to CD141⁺ DCs, the human cDC1 equivalent. CD141⁺ DCs exclusively express the C-type-lectin-like receptor CLEC9A, which is important for the regulation of CD8⁺ T cell responses. This study developed a new vaccine that harnesses a human anti-CLEC9A antibody to specifically deliver the immunogenic tumor antigen, NY-ESO-1 (New York esophageal squamous cell carcinoma 1), to human CD141⁺ DCs. The ability of the CLEC9A-NY-ESO-1 antibody to a

SUBMITTER: Masterman KA 

PROVIDER: S-EPMC7394304 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature